# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Biren Amin reiterates Solid Biosciences (NASDAQ:SLDB) with a Overweight and maintains $20 price target.
JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Neutral and lowers the price target from $12 ...
HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.
Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $21 ...
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.64) per share which met the analyst consensus estimate. This i...